Aaron Miller, MD
Pulmonary Disease · Columbia, MONPI 1760724223
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $82,540 of the $110,536 with a category attached, or 74.7%. Merck accounts for 60.0% of it on its own, with 11 other manufacturers making up the rest. 2025 is the largest year on record at $47,491, more than ten times the $208 reported in 2019. Among pulmonary disease clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 306 payments — averaging $361.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$66K
- Actelion Pharmaceuticals US, Inc.$41K
- United Therapeutics Corporation$2K
- Bayer$1K
- Sanofi-aventis U.S. LLC$97
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$87
- plus $195 from 6 others
Across 12 payments — averaging $3595.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$27K
- Merck$16K
What the payments were for
- Consulting fees$6,6956%
- Speaking & faculty fees$82,54075%
- Travel & lodging$13,82713%
- Food & beverage$7,0726%
- Education$4020%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 84 | $66,345 |
| Actelion Pharmaceuticals US, Inc. | 144 | $40,970 |
| United Therapeutics Corporation | 44 | $1,774 |
| Bayer | 22 | $1,068 |
| Sanofi-aventis U.S. LLC | 1 | $97 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $87 |
| Philips North America LLC | 4 | $66 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| Acist Medical Systems, Inc. | 1 | $34 |
| Cordis US CORP. | 1 | $23 |
| Baxter Healthcare | 1 | $19 |
| AstraZeneca | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$110,536 in reported general payments places this provider in the 90th percentile of 295 pulmonary disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tyvaso DpiTreprostinil | 151 | $3,705,642 |
| OpsumitMacitentan | 193 | $2,423,461 |
| AdempasRiociguat | 124 | $1,692,992 |
| WinrevairSotatercept-Csrk | 50 | $990,598 |
| UptraviSelexipag | 34 | $797,344 |
| Orenitram ErTreprostinil Diolamine | 75 | $595,431 |
| Ambrisentan | 71 | $203,085 |
| Tadalafil | 145 | $158,233 |
| TezspireTezepelumab-Ekko | 18 | $77,448 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 43 | $37,044 |
| EliquisApixaban | 25 | $21,375 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $13,522 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 20 | $13,032 |
| CorlanorIvabradine Hcl | 14 | $8,398 |
| FarxigaDapagliflozin Propanediol | 13 | $7,372 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $40,970 | $3,220,805227 claims |
| BayerAdempas | $1,068 | $1,692,992124 claims |
| MerckWinrevair | $66,345 | $990,59850 claims |
| AstraZenecaTezspire, Farxiga, Symbicort | $16 | $91,62758 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 295 pulmonary disease providers in Missouri.
Other pulmonary disease in Columbia
- Jason GoodinColumbia$17K
- Humam FarahHannibal$840K
- Derek ByersSaint Louis$835K
- Alexander ChenSaint Louis$679K
- Joseph OjileSaint Louis$538K
- Munaf SiyamwalaIndependence$413K
- Edward CharbekSaint Louis$372K
- Adeel KhanWashington$316K
- Marin KollefSaint Louis$264K
- Praveen ChennaSaint Louis$255K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.